GMAB Stock Recent News

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate technology platforms   The U.S. Food and Drug Administration (U.S. FDA) approved EPKINLY ® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of conditional marketing authorization of TEPKINLY ® (epcoritamab) for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy Tivdak ® (tisotumab vedotin-tftv) received full U.S. FDA approval to treat recurrent or metastatic

Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is updating its 2024 financial guidance last published on May 2, 2024, following the acquisition of ProfoundBio, Inc. (ProfoundBio). The revised guidance reflects an updated revenue outlook, incremental R&D investment to support the advancement of ProfoundBio's clinical programs, primarily rinatabart sesutecan (Rina-S), as well as acquisition and integration related charges.

Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement The overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab. BioNTech SE (BioNTech) has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement.

The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?

The consensus price target hints at a 52.3% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.